Investigational drug · Phase 2
PCV15
Also called: 15-valent pneumococcal conjugate vaccine
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Pneumococcal Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
8
Any phase or sponsor naming "PCV15"
First trial start
2024
Jul 25, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PCV15", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pneumococcal Disease
Largest trials
Live from ClinicalTrials.gov: studies naming "PCV15" as an intervention, largest first.
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05420961 · 717 participants · Start Jul 12, 2022 · Primary completion May 16, 2023
Drug: V116; PCV15 and 1 more · For: Pneumonia, Pneumococcal
Sites: Birmingham, Alabama; Glendale, Arizona; Tempe, Arizona · 51 sites in all
- A Study to Learn About How a New Pneumococcal Vaccine Works in InfantsPivotal-lookingActive, not recruiting
PfizerPfizer (PFE)
NCT06524414 · 605 participants · Start Jul 25, 2024 · Primary completion Mar 4, 2027
Drug: PG4; 20-valent pneumococcal conjugate vaccine (20vPnC) and 1 more · For: Pneumococcal Disease
Sites: Fayetteville, Arkansas; Jonesboro, Arkansas; La Puente, California · 67 sites in all
- Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05696080 · 518 participants · Start Feb 13, 2023 · Primary completion Feb 16, 2024
Drug: V116; Placebo and 2 more · For: Pneumococcal Infection
Sites: Mesa, Arizona; Hialeah, Florida; West Palm Beach, Florida · 44 sites in all
- Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU-WAY PED)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT03921424 · 407 participants · Start Nov 5, 2019 · Primary completion May 3, 2021
Drug: V114; Prevnar 13™ and 1 more · For: Pneumococcal Infections
Sites: Johannesburg, South Africa; Cape Town, South Africa; Paarl, South Africa · 13 sites in all
- Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of AgePivotal-lookingCompleted
PfizerPfizer (PFE)
NCT05489328 · 394 participants · Start Aug 15, 2022 · Primary completion Oct 7, 2022
Drug: 13vPnC; PCV15 · For: Pneumococcal Disease
Sites: Tustin, California; Walnut Creek, California; Milford, Connecticut · 18 sites in all
- Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05393037 · 313 participants · Start Jul 13, 2022 · Primary completion Jul 13, 2023
Drug: V116; Placebo and 3 more · For: Pneumococcal Disease
Sites: Phoenix, Arizona; Washington D.C., District of Columbia; Ft. Pierce, Florida · 20 sites in all
- Carriage to Assess Protection of New Pneumococcal Vaccines - PCV15Pivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT06731374 · 106 participants (planned) · Start Feb 24, 2025 · Primary completion Dec 2025
Drug: PCV15; Streptococcus pneumoniae serotype 3 and 1 more · For: Pneumococcal Disease; Pneumococcal Carriage
Sites: Liverpool, United Kingdom; Oxford, United Kingdom
- MISP 60528 Pneumococcal VaccinationTerminated
Montefiore Medical CenterAcademic, hospital or other
NCT04845945 · 4 participants · Start Jun 10, 2021 · Primary completion Aug 24, 2024
Drug: PCV15 · For: Heart Transplant Infection Prevention
Sites: The Bronx, New York
Newest research
PubMed records naming it or its code names, newest first.
- Pneumococcal vaccination for prevention of infection and diagnosis of antibody deficiency in the extended conjugated vaccine era.
Shieb M, Li G, Joshi A · Curr Opin Pediatr 2026
- The mutual effects on safety and immunogenicity of combined vaccination with 15-valent pneumococcal conjugate vaccine and adsorbed acellular DPT in 3-month healthy infants: A randomized, open-label, controlled, phase III clinical trial.
Lu-Lu P, Hong-Ze M, Zhao G, et al. · Hum Vaccin Immunother 2026
- The relative immunogenicity of 20-valent and 15-valent pneumococcal conjugate vaccines: A systematic review and network meta-analysis.
Valentini I, Strangi EA, Baccarini G, et al. · Hum Vaccin Immunother 2026
- Estimating clinical and economic impacts and cost-effectiveness of introducing 20-valent pneumococcal conjugate vaccine in Taiwan's pediatric National Immunization Program and impacts of a delayed implementation.
Yang YM, Wang YW, Ta A, et al. · Hum Vaccin Immunother 2026
- Projected health and economic impact of PCV20 vaccination in UK children: a dynamic transmission model.
Warren S, Said J, Trim J, et al. · Expert Rev Vaccines 2026
- Invasive Pneumococcal Disease burden, clinical characteristics, serotypes' distribution, immunization status and antimicrobial resistance: Evidence from 12-year hospital-based surveillance and cost analysis.
Vecchio R, Iskandar E, Gentile L, et al. · Hum Vaccin Immunother 2026
Also in development for Pneumococcal Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Pfizer.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.